Brief: Grand Pharmaceutical Says GPN01530 Approved For Clinical Trials In The United States
17/12/2025 10:00
Dec 17 (Reuters) - Grand Pharmaceutical Group Ltd 0512.HK: GPN01530 APPROVED FOR CLINICAL TRIALS IN THE UNITED STATES FDA APPROVES GPN01530 FOR PHASE I/II CLINICAL STUDY Further company coverage: 0512.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement